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Aims:  Preeclampsia (PreE) is a 
prevalent hypertensive disorder of 
pregnancy leading to a death every 
minute worldwide. Predictive and 
preventative challenges in PreE stems 
from its unclear early-pregnancy 
etiology. Arginine vasopressin (AVP) 
secretion, as measured by copeptin, 
activates the stress response system 
and is a novel, early pregnancy 
predictor of PreE. In addition, elevated 
AVP is associated with stress, 
depression and pain. Our Precision 
Healthcare goal is to understand how 
AVP-associated changes in depression 
and pain affect the phenotype of PreE to 
develop preventative and therapeutic 
modalities against it. We hypothesize 
that in humans, antecedent depression 
and pain affects early pregnancy AVP 
secretion/copeptin which will be 
differentially predictive of PreE. To 
address this hypothesis we aim to 1) 
determine the association of maternal 
plasma copeptin and measures of 
depression and pain throughout human 
gestation and 2) determine how 
depression and pain through gestation 
affects an early pregnancy copeptin 
based prediction model of preeclampsia.  
Methods: This nested case control 
study will use banked, coded, clinically-
annotated maternal plasma from the 
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(MFTB, IRB# 200910784) from pregnant 
and postpartum women. Copeptin will 
be measured using a commercial 
enzyme-linked immunosorbent assay. 
All clinical data including depression 
measures (Patient Health 
Questionnaire-9 and Edinburgh 
Postnatal Depression Scale) and pain 
measures (Numeric Rating Scale) will 
be extracted from Iowa Clinical Data 
Warehouse associated with the MFTB. 
Regression modeling and receiver 
operating characteristic curve analyses 
will be performed to evaluate the 
association of copeptin, depression, 
pain and PreE.    
Results   
Research in progress.  
Conclusions   
Research in progress 
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